Juniper Pharmaceuticals names new director
12 September 2017 -

Juniper Pharmaceuticals (Nasdaq: JNP), a US-based women's health therapeutics company, announced yesterday that it has named Jennifer Good as its director.

Good will serve as a member of both the Audit Committee and Compensation Committee. She is the co-founder, president, and chief executive officer at Trevi Therapeutics. Prior to founding Trevi, she served as president and chief executive officer and as chief financial officer at Penwest Pharmaceuticals, where she successfully led the transition of Penwest Pharmaceuticals from a development stage company to a profitable commercial stage company generating annual revenues in excess of USD50m and negotiating the sale of the company to its major partner.

Alicia Secor, Juniper's president and CEO, 'We are excited to have Jennifer join the Juniper team. She is an industry veteran with executive operational experience. With her expertise in financial leadership, she brings to our board a track record of setting and executing on business and financial strategies and is skilled at identifying and negotiating value-creating partnerships and collaborations. In addition, with her background as both a CEO and CFO, Jennifer is also particularly well-qualified to join our Audit Committee. We look forward to her contributions as we work to achieve our corporate goals.'